3FDA. Providing clinical evidence of effectiveness for human drug and bi- ological products [ EB/OL]. http://www. fda. ggv/cder/guidance/, 2007 - 11 - 12.
4Eclat DS, Liebson PR, Mitchell LB ,et al . Mortality and mobidity in patients receiving encainide flecainide , or placebo. The cardiac arrlaythmia suppression trial [ J ]. N Engl J Med, 1991 ; 329 : 781 - 788.
5Fleming TR. Surrogate endpoints and FDA' s accelerated approval process [ J]. Health Aff,2005 ;24:67 - 68.
